How to Select the Right Cost-Effectiveness Model?

被引:3
作者
van Haalen, H. G. M. [1 ,2 ]
Severens, J. L. [1 ]
Tran-Duy, A. [3 ,4 ,5 ]
Boonen, A. [3 ,4 ]
机构
[1] Erasmus Univ, Inst Hlth Policy & Management, NL-3062 PA Rotterdam, Netherlands
[2] AstraZeneca, Zoetermeer, Netherlands
[3] Maastricht Univ, Div Rheumatol, Dept Internal Med, Med Ctr, NL-6229 HX Maastricht, Netherlands
[4] Caphri Sch Publ Hlth & Primary Care, NL-6229 HX Maastricht, Netherlands
[5] Maastricht Univ, Med Ctr, Dept Clin Epidemiol & Med Technol Assessment, NL-6229 HX Maastricht, Netherlands
关键词
TUMOR-NECROSIS-FACTOR; SEVERE RHEUMATOID-ARTHRITIS; MODIFYING ANTIRHEUMATIC DRUGS; FACTOR-ALPHA INHIBITORS; ECONOMIC-EVALUATION; TREATMENT STRATEGIES; INADEQUATE RESPONSE; BIOLOGIC AGENTS; HEALTH-CARE; ETANERCEPT;
D O I
10.1007/s40273-014-0139-9
中图分类号
F [经济];
学科分类号
020101 [政治经济学];
摘要
In the current study, we propose an approach for selection of a model that is transferable to a specific decision-making context (in this case, the Netherlands), using the case of rheumatoid arthritis (RA). The objectives of this study were (a) to perform a systematic literature review to identify existing health economic evaluation models for economic evaluation of disease-modifying antirheumatic drugs (DMARDs) in RA; and (b) to test the appropriateness of a stepwise model-selection process. First, we searched Medline and Embase to identify relevant studies in the English language, published between 1 January 2002 and 31 August 2012. From the included studies, all unique models were identified. Second, we applied a multi-step approach to model selection. Models that did not meet all minimal methodological and structural requirements based on the Outcome Measures in Rheumatology (OMERACT) criteria were excluded. Next, models were assessed on the basis of their fit when transferred to the Dutch health care setting. The criteria for model fit were transferability factors, as published by Welte et al., after exclusion of those that were deemed transferable by simple adaptation. Finally, the remaining models underwent a general quality check using the Philips checklist. Models showing good fit and high quality were considered to be transferable to the Dutch health care setting, using simple adaptation. The systematic literature search identified 498 articles, which included 33 unique health economic evaluation models. Only six models passed the minimal methodological and structural requirements. Two of these models had an imperfect transferability fit to the Dutch health care setting, according to the Welte method. The remaining four models were, according to the Philips method, of good quality and were expected to be transferable by a simple adaptation. This study introduces a stepwise approach for selecting health economic evaluation models that are transferable by a simple adaptation. The approach seems feasible and can be applied in various therapeutic areas, provided that the minimal methodological and structural requirements are defined accordingly. Availability of health economic evaluation models coupled with structured model selection could improve the efficiency, quality and comparability of health economic research.
引用
收藏
页码:429 / 442
页数:14
相关论文
共 68 条
[1]
Epidemiology of adult rheumatoid arthritis [J].
Alamanos, Y ;
Drosos, AA .
AUTOIMMUNITY REVIEWS, 2005, 4 (03) :130-136
[2]
[Anonymous], 2012, SCI OP ENT OP DAT OP
[3]
Bansback N, 2008, PHARMACOECONOMICS, V26, P395, DOI 10.2165/00019053-200826050-00004
[4]
Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden [J].
Bansback, NJ ;
Brennan, A ;
Ghatnekar, O .
ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (07) :995-1002
[5]
An overview of economic evaluations for drugs used in rheumatoid arthritis -: Focus on tumour necrosis factor-α antagonists [J].
Bansback, NJ ;
Regier, DA ;
Ara, R ;
Brennan, A ;
Shojania, K ;
Esdaile, JM ;
Anis, AH ;
Marra, CA .
DRUGS, 2005, 65 (04) :473-496
[6]
The cost effectiveness of infliximab for severe treatment-resistant rheumatoid arthritis in the UK [J].
Barbieri, M ;
Wong, JB ;
Drummond, M .
PHARMACOECONOMICS, 2005, 23 (06) :607-618
[7]
Barton P, 2004, HEALTH TECHNOL ASSES, V8, P1
[8]
Development of the Birmingham Rheumatoid Arthritis Model: past, present and future plans [J].
Barton, Pelham .
RHEUMATOLOGY, 2011, 50 :iv32-iv38
[9]
Beaudet Amelie, 2011, J Med Econ, V14, P357, DOI 10.3111/13696998.2011.579213
[10]
Modelling Cost-Effectiveness of Biologic Treatments Based on Disease Activity Scores for the Management of Rheumatoid Arthritis in Spain [J].
Beresniak, Ariel ;
Ariza-Ariza, Rafael ;
Francisco Garcia-Llorente, Jose ;
Ramirez-Arellano, Antonio ;
Dupont, Danielle .
INTERNATIONAL JOURNAL OF INFLAMMATION, 2011, 2011